Condition or disease | Intervention/treatment | Phase |
---|---|---|
Symptomatic Severe Aortic Stenosis | Device: Portico™ NG Valve and FlexNav™ Delivery System | Not Applicable |
The Portico NG Approval study will be conducted as a prospective, multi-center, international, single-arm investigational study.
Up to 189 (includes up to 20 roll-ins) high or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Portico NG Transcatheter Aortic Heart Valve implantation will undergo Portico™ NG Valve implantation via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement) procedure.
Subjects participating in the clinical study will be followed for a total of 12 months with data collected at screening, baseline, procedure, prior to hospital discharge, and follow-up at 30 days, 12 months and annually at 2, 3, 4 and 5 years.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 189 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Devices under investigation in this clinical study include the Portico™ NG Valve (23mm, 25mm, 27mm and 29mm sizes), FlexNav™ Delivery System(s) (small and large) and Portico™ NG Loading System(s) (small and large), all of which are currently approved for investigational use only. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis |
Actual Study Start Date : | September 17, 2019 |
Estimated Primary Completion Date : | June 2021 |
Estimated Study Completion Date : | July 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Portico™ NG valve, FlexNav™ Delivery System
Portico valve implantation with the new generation Portico NG valve (23mm, 25mm, 27mm and 29mm sizes), second-generation FlexNav Delivery system (small and large) and Portico™ NG Loading System(s) (small and large)
|
Device: Portico™ NG Valve and FlexNav™ Delivery System
Subjects will undergo transcatheter aortic valve replacement (TAVR) with the new generation Portico NG valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
|
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Mira Tissari | +32 470 47 0942 | mira.tissari@abbott.com | |
Contact: Mary-Margaret Seale | +1 612 513 0822 | mary.seale@abbott.com |
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 4, 2019 | ||||||||
First Posted Date ICMJE | July 8, 2019 | ||||||||
Last Update Posted Date | March 12, 2021 | ||||||||
Actual Study Start Date ICMJE | September 17, 2019 | ||||||||
Estimated Primary Completion Date | June 2021 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||
Original Primary Outcome Measures ICMJE |
|
||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE |
Non-hierarchical composite of all-cause mortality, disabling stroke, life threatening bleeding, acute kidney injury (stage 3), or major vascular complications [ Time Frame: at 30 days ] | ||||||||
Original Secondary Outcome Measures ICMJE |
Secondary endpoint is freedom from mild or greater paravalvular leak [ Time Frame: at 30 days ] | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Portico NG Approval Study | ||||||||
Official Title ICMJE | Evaluation of the Portico™ NG (Next Generation) Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis | ||||||||
Brief Summary | The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Portico™ NG Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the rate of moderate or greater paravalvular leak at 30 days in a high or extreme surgical risk patient population to support CE (Conformité Européenne) Mark and FDA approval. | ||||||||
Detailed Description |
The Portico NG Approval study will be conducted as a prospective, multi-center, international, single-arm investigational study. Up to 189 (includes up to 20 roll-ins) high or extreme risk patients with symptomatic, severe native aortic stenosis who are determined by an independent subject selection committee to meet eligibility criteria for Portico NG Transcatheter Aortic Heart Valve implantation will undergo Portico™ NG Valve implantation via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR (transcatheter aortic valve replacement) procedure. Subjects participating in the clinical study will be followed for a total of 12 months with data collected at screening, baseline, procedure, prior to hospital discharge, and follow-up at 30 days, 12 months and annually at 2, 3, 4 and 5 years. |
||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Not Applicable | ||||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: Devices under investigation in this clinical study include the Portico™ NG Valve (23mm, 25mm, 27mm and 29mm sizes), FlexNav™ Delivery System(s) (small and large) and Portico™ NG Loading System(s) (small and large), all of which are currently approved for investigational use only. Masking: None (Open Label)Primary Purpose: Treatment |
||||||||
Condition ICMJE | Symptomatic Severe Aortic Stenosis | ||||||||
Intervention ICMJE | Device: Portico™ NG Valve and FlexNav™ Delivery System
Subjects will undergo transcatheter aortic valve replacement (TAVR) with the new generation Portico NG valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
|
||||||||
Study Arms ICMJE | Experimental: Portico™ NG valve, FlexNav™ Delivery System
Portico valve implantation with the new generation Portico NG valve (23mm, 25mm, 27mm and 29mm sizes), second-generation FlexNav Delivery system (small and large) and Portico™ NG Loading System(s) (small and large)
Intervention: Device: Portico™ NG Valve and FlexNav™ Delivery System
|
||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
189 | ||||||||
Original Estimated Enrollment ICMJE |
140 | ||||||||
Estimated Study Completion Date ICMJE | July 2026 | ||||||||
Estimated Primary Completion Date | June 2021 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 18 Years to 100 Years (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | Australia, Denmark, Italy, United Kingdom, United States | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT04011722 | ||||||||
Other Study ID Numbers ICMJE | ABT-CIP-10297 ABT-CIP-10308 ( Other Identifier: Abbott ) |
||||||||
Has Data Monitoring Committee | Yes | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Responsible Party | Abbott Medical Devices | ||||||||
Study Sponsor ICMJE | Abbott Medical Devices | ||||||||
Collaborators ICMJE | Not Provided | ||||||||
Investigators ICMJE | Not Provided | ||||||||
PRS Account | Abbott Medical Devices | ||||||||
Verification Date | March 2021 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |